Search
Biotech lab technologies expert Bob Gantzer talks about the digital lab book, rovers, and future technologies still to come in biotech
The VP of Lab Technologies at Aera Therapeutics describes what lab work was like before technology digitized and dramatically changed...
Oct 1, 2024
Mathai Mammen provides an update on the latest at FogPharma, and his philosophy of following the cadence of science, not the calendar
The Chairman and CEO of FogPharma describes the progress the company has made this year, including on the lead β-catenin/TCF4 inhibitor...
Oct 1, 2024
Seattle based Shape Therapeutics is aiming to reprogram cells by delivering guide RNAs via AAV - it has partnerships with Otsuka and Roche
Ron Hause, SVP, Head of AI, describes Shape's approach, which is meant to be a one time treatment without introducing any inheritable DNA...
Oct 1, 2024
Dyno Therapeutics is using AI to develop next generation AAV vectors for gene therapies
Co-Founder & CSO Adrian Veres and Head of Stewardship Tyson Bertmaring describe the shortcomings of wild type AAV that Dyno is trying to...
Oct 1, 2024
Benchling Co-Founder and CEO Sajith Wickramasekara kicks off Benchtalk 2024 and highlights new feature announcements for this software platform that powers the biotech sector
He describes the three main areas of Benchling's new features: Scaling the wet lab, powering the dry lab, and creating an open platform...
Oct 1, 2024
Immuno-Oncology experts Zhen Su and Kristen Hege discuss the latest in the field and preview #SITC24
Dr. Su and Dr. Hege talk about solving the cell therapy solid tumor challenge, the latest in bi-specifics, her recent hike of the Pacific...
Oct 1, 2024
ARS Pharmaceuticals recently received FDA approval for neffy, epinephrine in a nasal spray format for the treatment of allergic reactions like anaphylaxis
CEO Richard Lowenthal explains the science behind how it works, describes the launch plans, and discusses an additional indication to be...
Sep 30, 2024
Innovation Day San Diego: Palm Therapeutics is focused on developing palmitoylation targeted therapies
Co-Founder and CEO Andrew Rudd describes how the company is focused on this post translational modification as a drug target. The first...
Sep 27, 2024
Innovation Day San Diego: The director of UCSD's Center for RNA Technologies and Therapeutics shares his thoughts on the RNA field
Gene Yeo describes the latest advances in RNA and discusses mRNA, RNAi, antisense, exon skipping and more.
Sep 27, 2024
Innovation Day San Diego: The founder of San Diego based Resolute Science describes how the company aims to use macrophages to deliver toxic payloads to tumors
A resident company of JLABS @ San Diego, Faith Barnett describes how Resolute is creating "Macrophage Targeted Conjugates" to treat...
Sep 27, 2024
Houston Oncology Summit: The Cancer Focus Fund is closing on its second fund - it's a unique model that helps companies with knowhow and trial support at MD Anderson
General Partner Ross Barrett talks about how a new, larger fund will enable them to invest in more companies, and he shares some...
Sep 26, 2024
Houston Oncology Summit: MD Anderson's Chief Data & Analytics Officer describes the impact of the digitization of medicine
As a practicing clinician, Caroline Chung became increasingly focused on digital solutions. Today, she tells us how it is impacting...
Sep 26, 2024
Houston Oncology Summit: Oppenheimer analysts Jeff Jones and Jay Olson talk radiopharmaceuticals and antibody-drug conjugates
Jeff Jones notes how radioisotopes are being added to more than just antibodies, and calls out upcoming data from Perspective...
Sep 26, 2024
Houston Oncology Summit: MD Anderson Professor of Immunology Michael Curran talks turning cold tumors hot, including work by his company ImmunoGenesis
He discusses pathways that could play a role in helping solve this problem, including combinations with ADCs, STING and CD47, and work by...
Sep 26, 2024
Houston Oncology Summit: Oppenheimer analyst Matt Biegler discusses the breast cancer space and learnings from the conference
Matt Biegler summarizes a breast cancer panel from the conference and talks about recent data from Relay and upcoming data from Gilead....
Sep 26, 2024
Houston Oncology Summit: MD Anderson's Katy Rezvani, an expert in NK cell therapies, gives an overview of what is in development in this space
She describes the properties that she believes give NK cells an edge over T-cells, and discussed work in cell therapies, engagers, and...
Sep 26, 2024
Houston Oncology Summit: MD Anderson's John Heymach, a leading expert in lung cancer, talks about the latest in TKI's, KRAS, Bi-specifics, and more
John Heymach gives an overview of how TKIs are progressing in the EGFR and HER2 space, his thoughts on the recent VEGF x PD1 data that...
Sep 26, 2024
Houston Oncology Summit: MD Anderson's Ferran Prat describes how companies can partner with MD Anderson and what technologies excite him
Ferran Prat, who is in charge of external innovation at MD Anderson, talks about what makes for a good partnership, and he also describes...
Sep 26, 2024
Basel headquartered Nouscom is developing cancer vaccines with a platform that enables it to pack a high number of neoantigens into its product candidates
CEO Marina Udier describes how the company is developing an off the shelf product that includes over 200 neoantigens, a personalized...
Sep 25, 2024
Basel based Anaveon is engineering cytokines to solve the problem of T-cell exhaustion
Co-Founder & CEO Andreas Katopodis describes the company’s three primary programs: a non-specific fusion protein that blocks the alpha...
Sep 25, 2024
.png){kind=logo}
